Researcher in Cancer Immunotherapy Full-time

Job Title

The project involves validation of new T-cell receptor-based immunotherapies in vitro for safety and efficacy, and in advanced in vivo mouse models. A wide spectrum of methodologies will be used, including standard molecular biology techniques such as DNA/RNA isolation and plasmid preparation, retroviral transduction of T cells, culture of primary T cells, multiparameter (up to 12 colors) flow cytometry assays including functional T-cell assays (cytokine release, cytotoxicity, proliferation), culture of organoids, establishment of patient-derived xenograft models and evaluation of TCR-T cell therapy in such models.

Olweus is Head of the Dept. of Cancer Immunology at Oslo University Hospital Radiumhospitalet and leads a research group in the department and holds a position as Professor at the University of Oslo (UiO). The main focus of the research group of Olweus is to develop novel T-cell receptor-based cancer immunotherapies and new technologies for target and TCR identification, and to couple clinical immunotherapy trials with penetrating mechanistic analyses. The research is performed in an interdisciplinary and translational program. The enthusiastic research team of 20 people is highly international and conducts research in close collaboration with world-leading international collaborators at institutions such as Netherlands Cancer Institute and Karolinska Institutet.